tbuckley/cabot-search huggingface dataset:
CLINICAL IMPLICATIONS OF DIABETES AMONG PATIENTS WITH LEFT VENTRICULAR ASSIST DEVICES
Authors: Cesar Caraballo, Neal Ravindra, P. Elliot Miller, Megan McCullough, Catherine Mezzacappa, Clancy Mullan, Juliana Lawrence, Fouad Chouairi, Nihar R. Desai, Tariq Ahmad
Journal: Journal of the American College of Cardiology (2020)
RESTING HEART RATE DISTURBED THE CALCULATION OF CORONARY FLOW RESERVE IN PATIENTS WITH CORONARY MICROVASCULAR DISEASE
Authors: Chenghu Guo, Mingjun Xu, Yu Zhang, Yan Liu, Peixin Lin, Lijuan Lv, Jichen Pan, Mengmeng Li, Mei Zhang
Journal: Journal of the American College of Cardiology (2020)
PREDICTORS OF DEATH OR HEART FAILURE HOSPITALIZATION IN PATIENTS WITH FUNCTIONAL MITRAL REGURGITATION: SUB-ANALYSIS FROM THE COAPT TRIAL
Authors: Neeraj N. Shah, William A. Gray, Mahesh Madhavan, Sorin J. Brener, JoAnn Lindenfeld, William Abraham, Paul A. Grayburn, Saibal Kar, None Kar, Scott Lim, Jacob M. Mishell, Brian Whisenant, Zixuan Zhang, Michael Mack, Gregg W. Stone
Journal: Journal of the American College of Cardiology (2020)
MAKING SURVIVORSHIP MATTER: PREDICTING CANCER THERAPY-RELATED CARDIAC DYSFUNCTION IN WOMEN WITH HER2+ BREAST CANCER THROUGH INTEGRATIVE DIAGNOSTIC APPROACHES
Authors: Dakota Gustafson, Crizza Ching, Faisal Alibhai, Natalie Galant, Jason Fish, Paaladinesh Thavendiranathan
Journal: Journal of the American College of Cardiology (2020)
Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant
Authors: Alessandro Cucchetti, Matteo Serenari, Carlo Sposito, Stefano Di Sandro, Cristina Mosconi, Ilaria Vicentin, Enrico Garanzini, Vincenzo Mazzaferro, Luciano De Carlis, Rita Golfieri, Carlo Spreafico, Angelo Vanzulli, Vincenzo Buscemi, Matteo Ravaioli, Giorgio Ercolani, Antonio Daniele Pinna, Matteo Cescon
Journal: Journal of Hepatology (2020)
Phase I study of rapamycin (R) in combination with CYP3A4 modifier, ketoconazole (K), in patients with advanced malignancies
Authors: E. E. Cohen, K. Moshier, F. Innocenti, M. Kocherginsky, L. House, J. Ramirez, S. D. Undevia, G. F. Fleming, M. J. Ratain
Journal: Journal of Clinical Oncology (2006)

3061 Background: R is currently FDA approved for the treatment of renal allograft rejection but mTOR is a relevant target in several cancer types. K, a CYP3A4 inhibitor, increases the area under the concentration curve (AUC) of R and co-administration of R and K can overcome poor R bioavailability and decrease costs substantially. The aims of this study were to find the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of R administered weekly in combination with K and describe the pharmacokinetics (PK) of the combination in patients with advanced malignancies. Methods: R and K were administered concurrently to successive cohorts of patients. R starting dose was 1 mg once weekly and was escalated by 1 mg per dose level. K was administered at a constant dose of 200mg BID 1 day prior to each R dose then 200 mg QD on the next 3 consecutive days. Results: 34 subjects (median age 60 years) have been enrolled. The highest dose of R administered thus far was 5mg without DLT. Most frequent toxicities observed of any grade included hyperglycemia (41%), lymphopenia (35%), hyperlipidemia (35%), fatigue (29%), anemia (26%), anorexia (24%), and nausea (24%). Observed grade 3 toxicities included 2 patients with lymphopenia, 2 patients with elevated transaminases, and 1 patient each with emesis and hyperglycemia. One patient experienced grade 3 confusion likely due to a drug-drug interaction of K with concomitant psychotropic medications. PK analysis of the first 2 dose levels confirms that K significantly increases Cmax and AUC of R ( Table ). R Cmax (with K) averaged 22.5 (11.7) and 27.4 (7.9) (mean/SD) ng/ml at the 1 and 2 mg dose levels, respectively. R AUC (with K) averaged 408.9 (225.4) and 663.8 (201.8) (mean/SD) ng*h/ml at the 1 and 2 mg dose levels, respectively. Conclusions: Low dose weekly R plus K results in potentially efficacious concentrations, as demonstrated by classic mTOR inhibitor toxicity. Higher doses on this schedule without K are probably also feasible, but would have higher costs. [Table: see text] No significant financial relationships to disclose.
Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: A systematic review and meta-analysis of clinical trials.
Authors: Liang Shi, Zhe Liu, Junfang Tang, Li Tong
Journal: Journal of Clinical Oncology (2013)

e19149 Background: Gefitinib and erlotinib are oral EGFR-TKIs widely used in advanced NSCLC. The reported incidence and risk of interstitial lung disease (ILD) events associated with gefitinib and erlotinib varies widely and has been inconsistently reported in trials. Therefore, we performed a systematic review and meta-analysis to determine the incidence and the relative risk (RR) associated with the use of gefitinib and erlotinib. Methods: PubMed databases were searched for articles published from January 2000 to October 2012, and abstracts from ASCO and ESMO meetings (2000-2012) were searched for relevant studies. Eligible studies included randomized controlled trials with gefitinib and erlotinib in advanced NSCLC patients. Summary incidence rates, RRs, and 95% CIs were calculated using fixed-effects or random-effects models, depending on the heterogeneity of the included studies. Results: 15,618 patients from 29 randomized controlled trials were selected for this meta-analysis. The overall incidence for all-grade ILD events was 1.2% (95% CI, 0.9% to 1.6%) among patients receiving gefitinib and erlotinib, with a mortality of 22.8% (95% CI, 14.6% to 31.0%). The summary incidence of fatal ILD events was 0.2% (95% CI, 0.1% to 0.3%) in 26 trials with available data. Compared with controls, the RR of all-grade and fatal ILD events was 1.53 (95% CI, 1.13 to 2.08; P = 0.006) and 1.96 (95% CI, 1.03 to 3.72, P = 0.041), respectively. After stratifying patients by study location (Asian versus non-Asian), the RR of all-grade ILD events was 2.00 (95% CI, 1.23 to 3.25) and 1.30 (95% CI, 0.88 to 1.91) for Asian studies and non-Asian studies, respectively. The analysis was also stratified for drug type, trial phase, treatment line, and studies quality, but no significant differences in RRs were observed in all subgroup analyses. Conclusions: Treatment with EGFR-TKIs gefitinib and erlotinib is associated with a significant increase in the risk of developing both all-grade and fatal ILD events in advanced NSCLC.
Psychosocial health in survivors of adult versus childhood cancer.
Authors: Charles A Phillips, Emily Hardcastle, Leandra Desjardins, Rachel Ruiz, Heather Bemis, Jasmine Arrington, Rachel Feldman, Alexandra Murphy, Bruce Compas, Debra L. Friedman
Journal: Journal of Clinical Oncology (2013)

9609 Background: The growing population of cancer survivors is characterized by two subgroups, those diagnosed as children and those diagnosed as adults. While psychosocial challenges are recognized in these survivors, little data exists comparing the psychosocial health between these two subgroups. Our objective is to compare adult and childhood cancer survivors for symptoms of depression, anxiety, somatic complaints, and post traumatic stress disorder (PTSD). Methods: At entry to the Vanderbilt Cancer Survivorship program, survivors of childhood and adult onset cancer, ages 15 – 55 years old, completed the Achenbach System of Empirically Based Assessment and the revised Impact of Event Scale. Using normalized T scores, independent sample t tests,and χ 2 analyses, responses were compared to normative data for each group and responses of the two survivor groups were compared to one another. Results: There were 172 survivors of childhood cancer (M= 9 years old at diagnosis) and 125 survivors of adult cancer (M= 41 years old at diagnosis). Childhood cancer diagnoses included hematologic cancer (56%), sarcoma (17%), brain tumor (8%), and other (19%). Adult cancer diagnoses included breast cancer (45%), colon cancer (8%), hematologic cancer (14%), sarcoma (4%), and other (29%). After adjusting for age-related population norms, adult survivors were significantly more likely to have symptoms of depression (p=.011), anxiety (p=.029), somatic problems (p=.043), and PTSD (p=.004) compared to their childhood counterparts. Compared to age-expected norms, significantly more adult, but not child, survivors scored in the clinical range for depression (29%, p&lt;.001; vs. 18% n.s) and somatic problems (23%, p=.013; vs. 12%; n.s.). Time elapsed from cancer diagnosis to completion of the questionnaires was not significantly correlated with any of the measures. Conclusions: Survivors of adult onset cancer face a significantly higher amount of psychologic distress, particularly depressive and somatic symptoms, compared to their childhood counterparts and age-expected norms. Analyses are ongoing to evaluate other demographic, disease, and treatment related risk factors that may contribute to this age-related phenomenon in order to develop interventions.
SODIUM TO CREATININE RATIO IN SPOT URINE IS A SIMPLE AND USEFUL MARKER FOR THE PREDICTION OF HEART FAILURE HOSPITALIZATION: POST-HOC ANALYSIS OF THE ESPRIT, EVALUATION OF SODIUM INTAKE FOR THE PREDICTION OF CARDIOVASCULR EVENTS IN JAPANESE HIGH-RISK PATIENTS, COHORT STUDY
Authors: Tsuneaki Sadanaga, Shinichi Hirota, Hideo Mitamura
Journal: Journal of the American College of Cardiology (2020)
Abstract 10190: Double or Compound Sarcomere Mutations Associated with Sudden Death Risk in Hypertrophic Cardiomyopathy in the Absence of Conventional Risk Factors
Authors: Christopher Semsarian, Martin Maron, Barry J Maron
Journal: Circulation (2011)

Background: Risk stratification strategies employing sarcomere gene mutational analysis have proved imprecise in hypertrophic cardiomyopathy (HCM). Additional genetic risk markers that reliably ide...
UNEXPECTED FINDING DURING MITRACLIP PROCEDURE: IMPORTANCE OF THOROUGH INTRAPROCEDURAL TRANSESOPHAGEAL ECHOCARDIOGRAPHY ASSESSMENT
Authors: Tom Kai Ming Wang, Rhonda Miyasaka, Grant W. Reed, Amar Krishnaswamy, Samir R. Kapadia, Serge Harb
Journal: Journal of the American College of Cardiology (2020)
CLINICAL PREDICTORS OF SUCCESSFUL WEANING FROM IMPELLA SUPPORT IN CARDIOGENIC SHOCK
Authors: Behnam Tehrani, Carolyn Rosner, Abdulla Damluji, Matthew William Sherwood, Alexander George Truesdell, Kelly Epps, Shashank S. Sinha, Mitchell Psotka, Lauren Cooper, Edward Howard, Ramesh Singh, Nadim Geloo, Scott Barnett, Shahram Yazdani, Anika Raja, Christopher R. DeFilippi, Charles Murphy, Shashank Desai, Christopher O'Connor, Wayne B. Batchelor
Journal: Journal of the American College of Cardiology (2020)
BENCH TEST FOR OPTIMAL REPETITIVE PROXIMAL OPTIMIZING TECHNIQUEUSING MULTIMODALITY IMAGING
Authors: Teruyoshi Kume, Ryotaro Yamada, Hiroshi Okamoto, Terumasa Koyama, Tomoko Tamada, Koichiro Imai, Yoji Neishi, Shiro Uemura
Journal: Journal of the American College of Cardiology (2020)
What role should the commercial food system play in promoting health through better diet?
Authors: Martin White, Emilie Aguirre, Diane T Finegood, Chris Holmes, Gary Sacks, Richard Smith
Journal: BMJ (2020)

<b>Martin White and coauthors</b> consider that the commercial food system has the potential to show leadership and support for dietary public health, but systemic change is needed first and this is likely to require governmental action
ARHGEF7 (β-PIX) Is Required for the Maintenance of Podocyte Architecture and Glomerular Function
Authors: Jun Matsuda, Mirela Maier, Lamine Aoudjit, Cindy Baldwin, Tomoko Takano
Journal: Journal of the American Society of Nephrology (2020)

Previous studies showed that Cdc42, a member of the prototypical Rho family of small GTPases and a regulator of the actin cytoskeleton, is critical for the normal development and health of podocytes. However, upstream regulatory mechanisms for Cdc42 activity in podocytes are largely unknown.We used a proximity-based ligation assay, BioID, to identify guanine nucleotide exchange factors that activate Cdc42 in immortalized human podocytes. We generated podocyte-specific ARHGEF7 (commonly known as β-PIX) knockout mice by crossing β-PIX floxed mice with Podocin-Cre mice. Using shRNA, we established cultured mouse podocytes with β-PIX knockdown and their controls.We identified β-PIX as a predominant guanine nucleotide exchange factor that interacts with Cdc42 in human podocytes. Podocyte-specific β-PIX knockout mice developed progressive proteinuria and kidney failure with global or segmental glomerulosclerosis in adulthood. Glomerular podocyte density gradually decreased in podocyte-specific β-PIX knockout mice, indicating podocyte loss. Compared with controls, glomeruli from podocyte-specific β-PIX knockout mice and cultured mouse podocytes with β-PIX knockdown exhibited significant reduction in Cdc42 activity. Loss of β-PIX promoted podocyte apoptosis, which was mediated by the reduced activity of the prosurvival transcriptional regulator Yes-associated protein.These findings indicate that β-PIX is required for the maintenance of podocyte architecture and glomerular function via Cdc42 and its downstream Yes-associated protein activities. This appears to be the first evidence that a Rho-guanine nucleotide exchange factor plays a critical role in podocytes.
THE SEXAGENARIAN 12-LEAD ECG: IS IT TIME FOR RETIREMENT?
Authors: Sameer Mehta, Francisco Fernandez, Carlos Villagran, Sebastian Niklitschek, Jorge Avila, Alejandra Frauenfelder, Daniel Vieira, Mariana Ceschim, Sohail Merchant, Akhil Vaid, Gladys Pinto, Isabella Vallenilla, Lilly Prieto, Genesis Perez del Nogal, Daniela Bou Daher, Maritza Luna, Samantha Quintero, Jorge Mazzini
Journal: Journal of the American College of Cardiology (2020)
PERICORONARY ADIPOSE TISSUE COMPUTED TOMOGRAPHY ATTENUATION IN DIFFERENT STAGES OF CORONARY ARTERY DISEASE: A CROSS-SECTIONAL STUDY
Authors: Andrew Lin, Nitesh Nerlekar, Jeremy Yuvaraj, Katrina Fernandes, Cathy Jiang, Damini Dey, Stephen J. Nicholls, Dennis TL Wong
Journal: Journal of the American College of Cardiology (2020)
Ectopic Gallbladder Mimicking Choledochal Cyst on Hepatobiliary Scintigraphy
Authors: Lin Zhang, Marian Gaballah, Zhe Wen, Hongming Zhuang
Journal: Clinical Nuclear Medicine (2020)

The gallbladder is generally located at the anterolaterally situated gallbladder fossa on the undersurface of the liver, whereas choledochal cyst, as a dilation of the common bile duct, is located more posteromedially. We reported an ectopically located gallbladder, which appeared to be a choledochal cyst on hepatobiliary scintigraphy in a 10-year-old girl.
Evaluation of Cyclosporine for the Treatment of DRESS Syndrome
Authors: Emily Nguyen, Daniel Yanes, Sotonye Imadojemu, Daniela Kroshinsky
Journal: JAMA Dermatology (2020)

This retrospective case-control study of 26 adults evaluates the use of cyclosporine A in the treatment of drug reaction with eosinophilia and systemic symptoms (DRESS syndrome) compared with standard systemic glucocorticosteroids.
Sentinel lymph node in prostate carcinoma: Methodology, feasibility, surgical, and oncological consequences, about 74 patients.
Authors: Claude Soler, Yves Perraud, Eric Gremillet, Corine Armand, Benjamin Geissler, Aline Steiner, Frederic Levigne
Journal: Journal of Clinical Oncology (2012)

e15109 Background: There are few studies in the field of prostatic sentinel lymph node (SLN) procedure: in the international literature at the most 10 publications are found. However the interest of urological surgeons and oncologists is growing fast. Goals of our study were: on the first hand to evaluate the rate of SLN SPECT-CT detection and the rate of SLN involvement, on the other hand to evaluate the incidence of the SLN biopsy results on the surgical and oncological management. Methods: 74 patients with prostate cancer were included. All patients had a Gleason score between 6 and 8. All patients were elected for a radical laparoscopic prostatectomy. Nanocis-Tc 99m was intratumorally injected, guided by transrectal ultrosonography. 2 injections of 0.6 ml in each lobe of the prostate were performed, depending on the size of the prostate. Patient underwent planar imaging and SPECT-CT 2 hours after injections. Surgery was performed 18 hours after SPECT-CT lymphoscintigraphy. Results: A lymphatic pelvic drainage was seen in 94,6 % (70/74) by SPECT-CT. Lymphatic drainage was on the right side (23), on the left side (15), or bilateral (32). The radioguided lymphadenectomy was assisted by a laparoscopic gamma-probe, the SLN detection rate was 97% (68/70); the average number of resected radioactive nodes was 1.6 (range 1 to 5). By all the ways, a limited pelvic lymph node dissection was performed in all 74 cases. An SLN involvement was found in 5 cases (5/68= 7.35%); in these 5 cases and in the 63 cases without SLN involvement, no metastatic involvement was found in the other lymph nodes, as well as in the 6 patients for which no SLN could be selectively resected (4 with no drainage seen and 2 not detected intra-operatively although visualized on lymphoscintigraphy). Conclusions: The low rate of lymphatic involvement is not surprising considering the Gleason score range 6 to 8 (low metastatic risk). So, the preliminary results are very attractive, especially for these patients that could have been falsely considered as N0. Our study is still in progress, and if these results are confirmed on a larger scale, then SLN procedure could be considered in the routine management of low risk prostatic carcinomas.
THE IMPACT OF CHRONIC TOTAL OCCLUSIONS ON OUTCOMES OF PATIENTS UNDERGOING CORONARY ARTERY BYPASS GRAFTING SURGERY: INSIGHTS FROM THE REGROUP TRIAL
Authors: Ronnie Ramadan, Scott Kinlay, Eileen M. Stock, Annette Phillips, Ellen J. DeMatt, Deepak Bhatt, Marco Zenati
Journal: Journal of the American College of Cardiology (2020)
PROGNOSTIC SIGNIFICANCE OF NON-ISCHEMIC FFR (&gt;0.80) IN LAD VERSUS NON-LAD LESIONS
Authors: Kulin Shah, Linle Hou, Bobby Ghosh, Ahmed A. Almomani, Mohan Mallikarjuna Rao Edupuganti, Jason Payne, Naga Venkata Pothineni, Sabha Bhatti, Zubair Ahmed, Barry F. Uretsky, Abdul Hakeem
Journal: Journal of the American College of Cardiology (2020)
Early Detection of Secondary Central Nervous System Lymphoma on PET/CT
Authors: Shaun Previn Appaduray, James Khoo, Nagavalli Somasundaram, Jason Chan, Sean Xuexian Yan
Journal: Clinical Nuclear Medicine (2020)

We present a case of secondary central nervous system relapse of lymphoma detected initially on PET/CT without corresponding findings on MRI. A 60-year-old lymphoma patient demonstrated an FDG-avid focus in left cerebellar hemisphere on restaging PET/CT. MRI brain showed no corresponding abnormality, and expectant management ensued. Six months later, she represented with metabolic progression of previously seen FDG-avid focus in left cerebellar hemisphere, now also manifesting as an enhancing mass on MRI. Posttreatment scan for presumed lymphoma relapse showed metabolic response. This case demonstrates the advantage of PET/CT over anatomical imaging to detect metabolic changes before structural changes become apparent.
Evaluating 18F-16B-fluoro-5α-dihydrotestosterone (FDHT) and FDG-PET as a measure of disease progression in metastatic castration resistant prostate cancer (mCRPC).
Authors: Karen A. Autio, Josef J. Fox, Coursen Walker Schneider, Heiko Schöder, John Humm, Dana E. Rathkopf, Susan F. Slovin, Daniel Costin Danila, Eric C. Haupt, Steven M. Larson, Howard I. Scher, Michael J. Morris
Journal: Journal of Clinical Oncology (2013)

5090 Background: Prostate Cancer Working Group 2 defines radiographic progression as new lesions on bone scan. Molecular imaging has potential as a biomarker that reflects both alterations in disease burden and tumor biology. FDG and FDHT PET capture glycolytic activity and androgen receptor (AR) expression and tracer binding, respectively. We examined these tracers in mCRPC patients (pts) at progression (POD) to determine patterns of relapse. Methods: mCRPC pts simultaneously enrolled in imaging and therapeutic clinical trials had FDG and/or FDHT PET scans performed at baseline (BL) and within 4 weeks of treatment (rx) discontinuation for protocol-defined POD. BL characteristics, rx, SUVmax, SUVmaxavg (average of 5 index lesions), and presence of new lesion(s) at POD were collected. ΔSUV was calculated relative to BL. Results: 44 mCRPC pts (86 BL PET scans, 84 scans at POD) receiving novel anti-androgens (eg, enzalutamide) (n=18), abiraterone (abi) (n=10), chemotherapy-based rx (n=5), prednisone (n=4), or other targeted rx (n=7) were included. Of those with PET POD, 75% (24/32) had &gt; 1 new lesion on FDG-PET and 96% (25/26) had &gt; 1 new lesion on FDHT. New lesions on FDHT were seen in 33% (6/18) of pts on novel anti-androgens as compared with 100% (10/10) on abi. Presence of a new FDG avid lesion was similar for both anti-androgens and abi (56% vs 60%). Conclusions: POD on FDG/FDHT is more frequently detected by a new lesion rather than ΔSUV in existing index lesions. This is possibly an underestimate of change as the BL scan and not the post-rx nadir scan were used as a comparator. AR and glycolytic activity at POD may be dependent on individual and treatment factors. Notably, a third of pts on anti-androgens had a new FDHT avid lesion at POD. Full lesional analysis of metastases may enhance our understanding of tumor biology at POD. Clinical trial information: NCT00588185. [Table: see text]
The rationale for the NEOCOR study: A new paradigm in locally advanced non-small cell lung cancer
Authors: S. S. Mitra
Journal: Journal of Clinical Oncology (2006)

17146 Background: Most patients with locally advanced NSCLC die of systemic disease. (Chevalier et al JNCI 1991). Concurrent chemoRT + adjuvant chemotherapy is the standard of care based on a metaanalysis comparing sequential chemoRT and Concurrent chemoRT, with median survival increased by 3 months. (Hak Choy ASCO 2003) The aim is to critically review all the sequential trials and the metaanalysis against a scientifically valid criteria. Methods: A scientifically valid trial comparing the two approaches: sequential chemoRT versus Concurrent chemoRT needs to have equivalent chemotherapy in both arms. It also needs to have equivalent chemoRT in both arms. There needs to be an adequate course of neoadjuvant chemotherapy (at least 4 cycles) in the sequential chemoRT arm. All the relevant sequential chemoRT versus concurrent chemoRT trials are critically reviewed. Results: The sequential chemoRT trials had an average of 2 cycles of chemotherapy before radiation. (Dillman et al CALGB B 8433, Sause et al ECOG 4588, Schaakee - Koning et al NEJM 1992). The Hak Choy metaanalysis is not a comparison of the two approaches: sequential chemoRT versus concurrent chemoRT. The WJLCG Furuse trial had more intensive chemotherapy in the concurrent arm. The GLOT-GFPC study had Etoposide chemotherapy on the concurrent arm. The LAMP study, Zatloukal - Zemanova study &amp; RTOG 9410 all had 2 cycles of chemotherapy followed by radiotherapy or concurrent chemoRT. SWOG 9504 using Cisplatin + Etoposide concurrent with Radiotherapy and adjuvant Docetaxel suggests that systemic treatment is important along with concurrent chemoRT. Betticher et al ( JCO 2003) showed that neoadjuvant chemotherapy with Docetaxel + Cisplatin achieves a 19% complete pathological response &amp; overall 66% response rate. Conclusions: Most patients with locally advanced NSCLC still die of systemic disease. Sequential chemoRT trials did not have adequately intensive chemotherapy regimens.Concurrent ChemoRT is a better form of RT. The author proposes a phase II trial of Neoadjuvant Chemotherapy with 4 cycles of Docetaxel 85 mg/m 2 D1+ Cisplatin 50 mg/m 2 D1 &amp; 2 followed by 2 cycles of Concurrrent Chemoradiotherapy with Cisplatin 50 mg/m 2 D1 &amp; D8 + Etoposide 50 mg/m 2 D1–5 concurrent with 61 Gy of Radiotherapy as a new paradigm in Locally advanced NSCLC. No significant financial relationships to disclose.